University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14544
Abstract: John W. Semple Keenan Research Centre for Biomedical Science of St. Michaels Hospital; Departments of Medicine and Pathology, University of Rochester School of Medicine, Rochester, NY, USA; Canadian Blood Services; Departments of Physiology and Anesthesia,… read more here.
Keywords: medicine; university chicago; toronto department; university ... See more keywords